Aug. 7 at 10:08 AM
Citizens⬆️
$CYTK's PT and said -- Strong MYQORZO launch with continued pipeline development, we reiterate our Market Outperform rating and increase our risk-adjusted, DCF-derived price target to
$110 from
$105 on Cytokinetics.
$EWTX $BMY TENX TECX
Citizens added—Yesterday afternoon, Cytokinetics reported 2Q26 financial results with the MYQORZO launches in the U.S. and Europe off to a fast start.
Product sales for the quarter were ~
$25MM, well ahead of our and consensus estimates.
Management commentary on the launch was strong, noting that launch velocity has exceeded expectations.
We view the initial launch metrics as compelling support that MYQORZO is both taking share from CAMZYOS and is expanding the CMI market.
